Transcript Pox-Protein Public Private Partnership (P5)

HIV Vaccine and Future
Strategies
Carl W. Dieffenbach, Ph.D.
Director
Division of AIDS, NIAID
July 2, 2013
This session will review past HIV vaccine efforts, as well as novel viral vectors
and advances in the design of vaccines to induce neutralizing antibodies.
A panel will discuss options to accelerate the development of a much needed
HIV vaccine.
ALVAC pox-based prime boost programme (RV144)
Punnee Pitisuttithum, Thailand
State of the art findings on HIV vaccines
Glenda Gray, South Africa
B cell response to vaccine candidates; antibody-based approaches
Dennis Burton, United States
Issues of engagement with populations at risk in HIV vaccine trials
Mitchell Warren, United States
Debate on future HIV vaccine strategies, including T response/other immune
responses to vaccines
Marcus Altfeld, United States
Dennis Burton, United States
Glenda Gray, South Africa
Punnee Pitisuttithum, Thailand
Mitchell Warren, United States
HIV Vaccine Efficacy Trials
No
NOTE: Phambili (HVTN 503) began to explore a regime similar to STEP in South Africa (not included).